Collegium Pharmaceutical (NASDAQ:COLL) has been assigned a $33.00 price target by stock analysts at Piper Jaffray Companies in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price points to a potential upside of 35.69% from the company’s previous close.

Several other brokerages have also recently commented on COLL. BidaskClub raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 29th. Needham & Company LLC raised their target price on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Jefferies Group raised their target price on Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, November 17th. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Monday, November 13th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $25.00.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at $24.32 on Tuesday. The firm has a market capitalization of $761.31, a price-to-earnings ratio of -8.16 and a beta of 0.42. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $25.02.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. The business had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. Collegium Pharmaceutical’s revenue was up 2814.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.13) earnings per share. sell-side analysts anticipate that Collegium Pharmaceutical will post -2.52 EPS for the current year.

In related news, insider Alison B. Fleming sold 4,601 shares of the stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the sale, the insider now directly owns 28,513 shares in the company, valued at $491,849.25. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the sale, the chief executive officer now owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,085,558 shares of company stock valued at $18,846,477. 25.76% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the stock. Nationwide Fund Advisors raised its holdings in shares of Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after acquiring an additional 2,802 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Collegium Pharmaceutical by 12.7% during the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock worth $365,000 after acquiring an additional 3,285 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after acquiring an additional 3,500 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Collegium Pharmaceutical by 12.8% during the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after acquiring an additional 5,136 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Collegium Pharmaceutical by 38.4% during the second quarter. The Manufacturers Life Insurance Company now owns 18,621 shares of the specialty pharmaceutical company’s stock valued at $233,000 after buying an additional 5,167 shares in the last quarter. Institutional investors and hedge funds own 79.99% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://theolympiareport.com/2018/01/23/collegium-pharmaceutical-coll-given-a-33-00-price-target-by-piper-jaffray-companies-analysts.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.